Daiichi Sankyo said on Friday it would invest about 1 billion euros ($1.07 billion) to expand a site near Munich, Germany, to boost its work on precision cancer drugs.

Merck & Co Inc. (MRK) and Daiichi Sankyo on Thursday said that the companies have withdrawn their application to the U.S. Food and Drug Administration (FDA) seeking permission to commercialize ...

Daiichi Sankyo has agreed to buy Ambit Biosciences for about $315 million, pointing to the potential of Ambit's drug candidate quizartinib, which is in late-stage trials for the treatment of acute ...

Japanese bulk-shipper Daiichi Chuo Kisen Kaisha sought bankruptcy protection in both Tokyo and New York Tuesday, with plans to restructure $1.5 billion in debt.

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable of reaching targets beyond the liver. The Japanese drugmaker is best ...

On June 1, Daiichi Sankyo Company Limited (OTC:DSNKY) and AstraZeneca (NASDAQ:AZN) announced promising results from 3 clinical trials: TROPION-Lung02, TROPION-Lung04, and NeoCOAST-2. These studies ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung cancer lived without their disease ...

Daiichi Sankyo Co. and partner AstraZeneca Plc shares fell the most in years after a study of their highly-anticipated lung cancer medicine raised questions about its safety and effectiveness.

Daiichi Sankyo's got a big revenue hurdle coming up, with top treatment Benicar set to lose patent protection next year. A black-box warning on its new drug Savaysa isn't helping matters. So ...

Sea Isle City residents have been spooked by the unexplained death of Daiichi Sankyo sales rep Tracy Hottenstein in February. Hottenstein, 35, had been in the Jersey Shore town for the annual ...